LAST WEEK TODAY! A summary of what was published on ProstateWarriors.com during the past week Hello fellow warriors! Please bear with me for one more week. Next Friday the annual AACR 2026 meeting begins, and I should finally have access to the clinical trial data that will be presented. It will be a very busy weekend! For […]
In a detailed review of two large clinical trials called ARCHES and PROSPER, doctors found that some patients experienced cancer growth visible on scans (known as radiographic progression) without seeing the usual rise in PSA blood levels, a key marker doctors often track. This mismatch highlights why regular imaging tests might be just as crucial […]
Castration-resistant prostate cancer (aka androgen pathway modulation resistant prostate cancer, APMR) is one of the toughest forms of prostate cancer to treat. It becomes resistant to hormone therapy, and current immunotherapies don’t work well on it. The main reason is that CRPC tumors create an immune-“cold” environment filled with M2 macrophages, a type of immune […]
A new study called ARAMON shows promising results for using darolutamide alone to treat non-metastatic or oligometastatic castration-sensitive prostate cancer (CSPC), as known as androgen pathway modulator sensitive (APMS), in men who have biochemical recurrence after surgery or radiation. This phase 2 trial enrolled 23 evaluable patients with PSA ≥0.2 ng/mL post-prostatectomy or ≥2 ng/mL […]
EXS74539, also called REC-4539, is an experimental cancer drug designed to block LSD1, a protein that helps some cancer cells grow and survive even when standard treatments fail. It is being tested in a phase 1 trial on people with selected solid tumors, including small-cell lung cancer, prostate cancer, ovarian cancer and others. This early-stage […]
TSL2109 is an experimental oral cancer drug being studied in people with advanced solid tumors, especially metastatic castration-resistant prostate cancer (aka androgen pathway modulation resistant prostate cancer, or APMR, God save us!) and advanced hormone receptor–positive, HER2-negative breast cancer. It is designed to hit two important targets at once, CDK4/6 and DYRK2, which may help […]
The Prostate Cancer Working Group 4 (PCWG4), published in February 2026, introduces patient-centric updates to advanced prostate cancer trial design, shifting from PCWG3’s clinical state model to a therapeutic indication framework. PCWG4 replaces outdated terms like “castration-resistant prostate cancer” (CRPC), “non-metastatic castration-resistant prostate cancer” (nmCRPC), “metastatic castration-resistant prostate cancer” (mCRPC), “hormone-sensitive prostate cancer” (HSPC), and […]
LAST WEEK TODAY! A summary of what was published on ProstateWarriors.com during the past week Happy Easter to all you warriors! While waiting for the AACR 2026 meeting, another update with interesting clinical and preclinical studies. Have a fantastic Easter! Stay strong and fight on! As usual, we also have a podcast if you prefer to listen […]
Prostate cancer becomes especially hard to treat when it turns resistant to hormone therapies like enzalutamide, largely because of a protein complex called PRC2 that shuts down genes needed to fight tumors. PRC2’s key parts, EZH2 and EED, fuel cancer growth, immune evasion, and drug resistance in prostate tumors, as well as others like endometrial […]
PSMA-targeted T-cell engagers have struggled in solid tumors because they don’t activate T cells strongly enough and the immune cells become exhausted quickly. QL535 solves this problem by adding a second co-stimulatory signal through CD2, a molecule on T cells that’s abundant in prostate cancer tumors. Researchers analyzed immune cells from 14 advanced prostate cancer […]